|
|
News Breaks | | | | October 4, 2012 | | 07:03 EDT |  | CTIC | Cell Therapeutics announced convertible preferred stock offering
Cell Therapeutics announced that it intends to offer and sell, subject to market and other conditions, 40,000 shares of its Series 17 Preferred Stock in an underwritten public offering. Each share of Series 17 Preferred Stock will have a stated value of $1,000 per share and will be convertible at the option of the holder, at any time after issuance, into shares of common stock prior to the automatic conversion of such shares in certain circumstances. | |
|
News For CTIC From The Last 14 Days Check below for free stories on CTIC the last two weeks. |
|
|
| June 17, 2013 | | 05:48 EDT |  | CTIC | Cell Therapeutics announces new data from Phase 1, 2 studies of pacritinib
 Subscribe for More Information | | | 05:41 EDT | | CTIC | Cell Therapeutics announces Phase 3 EXTEND results for Pixuvri
Cell Therapeutics announced results from sub-set analyses of data from the Phase 3 EXTEND, or PIX301, clinical trial of Pixuvri. The analyses evaluated the efficacy of Pixuvri in the subset of patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma, or NHL, as confirmed by central independent pathological review, who had failed 2 or 3 prior treatment regimens. Compared to physicians' choice of other agents given as monotherapy, single agent PIXUVRI resulted in 30% of patients who had previously received rituximab achieving a complete or unconfirmed durable complete response lasting on average 9.5 months with 67% of patients surviving at 2 years. In contrast, only 5.6% of patients in the comparator arm achieved an unconfirmed complete response. The benefit of Pixuvri has not be established in patients when used as 5th-line or greater chemotherapy. | | | June 12, 2013 | | 08:47 EDT |  | CTIC | Cell Therapeutics management to meet with UBS
Meeting to be held in Europe on June 12 hosted by UBS. | |
|
|
|
|
|
|
